Cargando…

Gemistocytic Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A Histopathological and Survival Analysis

Gemistocytic differentiation is a rare histological feature seen in IDH mutant Astrocytomas. The 2021 World Health Organization (WHO) retains the diagnosis of IDH mutant Astrocytoma with its classical histology and tumors with the rare histological pattern of gemistocytic differentiation. Gemistocyt...

Descripción completa

Detalles Bibliográficos
Autores principales: Hassan, Usman, Amer, Faizan, Hussain, Mudassar, Mushtaq, Sajid, Loya, Asif, Abu Bakar, Muhammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182877/
https://www.ncbi.nlm.nih.gov/pubmed/37193447
http://dx.doi.org/10.7759/cureus.37542
_version_ 1785041843571916800
author Hassan, Usman
Amer, Faizan
Hussain, Mudassar
Mushtaq, Sajid
Loya, Asif
Abu Bakar, Muhammad
author_facet Hassan, Usman
Amer, Faizan
Hussain, Mudassar
Mushtaq, Sajid
Loya, Asif
Abu Bakar, Muhammad
author_sort Hassan, Usman
collection PubMed
description Gemistocytic differentiation is a rare histological feature seen in IDH mutant Astrocytomas. The 2021 World Health Organization (WHO) retains the diagnosis of IDH mutant Astrocytoma with its classical histology and tumors with the rare histological pattern of gemistocytic differentiation. Gemistocytic differentiation has historically been associated with a worse prognosis and shorter survival, and this prognostic difference has not been investigated in detail in our population. A population-based retrospective study included 56 patients with IDH mutant Astrocytoma with Gemistocytic differentiation and IDH mutant Astrocytoma diagnosed between 2010 and 2018 in our hospital. Demographic, histopathological, and clinical parameters were compared between the two groups. Gemistocyte percentage, perivascular lymphoid infiltrates, and Ki-67 proliferation index were also analyzed. A Kaplan-Meier analysis was done to analyze any prognostic difference in the overall survival time between the two groups. Patients with an IDH mutant Astrocytoma having gemistocytic differentiation had an average survival period of 2 years, while patients diagnosed with an IDH mutant Astrocytoma had an average survival time of approximately 6 years. There was a statistically significant decrease in survival time (p = 0.005) for patients with tumors with gemistocytic differentiation. The percentage of gemistocytes and the presence of perivascular lymphoid aggregates did not correlate with survival time (p = 0.303 and 0.602, respectively). Tumors with gemistocytic morphology had a higher mean Ki-67 proliferation index (4.4%) than IDH mutant Astrocytoma (2.0%, p = 0.005). Our data suggest that IDH mutant Astrocytoma with Gemistocytic differentiation is an aggressive variant of IDH mutant Astrocytoma associated with a shorter survival time and an overall worse prognosis. This data might be helpful to clinicians in the future management of IDH mutant Astrocytoma with Gesmistocytic differentiation as an aggressive tumor.
format Online
Article
Text
id pubmed-10182877
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-101828772023-05-14 Gemistocytic Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A Histopathological and Survival Analysis Hassan, Usman Amer, Faizan Hussain, Mudassar Mushtaq, Sajid Loya, Asif Abu Bakar, Muhammad Cureus Genetics Gemistocytic differentiation is a rare histological feature seen in IDH mutant Astrocytomas. The 2021 World Health Organization (WHO) retains the diagnosis of IDH mutant Astrocytoma with its classical histology and tumors with the rare histological pattern of gemistocytic differentiation. Gemistocytic differentiation has historically been associated with a worse prognosis and shorter survival, and this prognostic difference has not been investigated in detail in our population. A population-based retrospective study included 56 patients with IDH mutant Astrocytoma with Gemistocytic differentiation and IDH mutant Astrocytoma diagnosed between 2010 and 2018 in our hospital. Demographic, histopathological, and clinical parameters were compared between the two groups. Gemistocyte percentage, perivascular lymphoid infiltrates, and Ki-67 proliferation index were also analyzed. A Kaplan-Meier analysis was done to analyze any prognostic difference in the overall survival time between the two groups. Patients with an IDH mutant Astrocytoma having gemistocytic differentiation had an average survival period of 2 years, while patients diagnosed with an IDH mutant Astrocytoma had an average survival time of approximately 6 years. There was a statistically significant decrease in survival time (p = 0.005) for patients with tumors with gemistocytic differentiation. The percentage of gemistocytes and the presence of perivascular lymphoid aggregates did not correlate with survival time (p = 0.303 and 0.602, respectively). Tumors with gemistocytic morphology had a higher mean Ki-67 proliferation index (4.4%) than IDH mutant Astrocytoma (2.0%, p = 0.005). Our data suggest that IDH mutant Astrocytoma with Gemistocytic differentiation is an aggressive variant of IDH mutant Astrocytoma associated with a shorter survival time and an overall worse prognosis. This data might be helpful to clinicians in the future management of IDH mutant Astrocytoma with Gesmistocytic differentiation as an aggressive tumor. Cureus 2023-04-13 /pmc/articles/PMC10182877/ /pubmed/37193447 http://dx.doi.org/10.7759/cureus.37542 Text en Copyright © 2023, Hassan et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Genetics
Hassan, Usman
Amer, Faizan
Hussain, Mudassar
Mushtaq, Sajid
Loya, Asif
Abu Bakar, Muhammad
Gemistocytic Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A Histopathological and Survival Analysis
title Gemistocytic Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A Histopathological and Survival Analysis
title_full Gemistocytic Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A Histopathological and Survival Analysis
title_fullStr Gemistocytic Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A Histopathological and Survival Analysis
title_full_unstemmed Gemistocytic Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A Histopathological and Survival Analysis
title_short Gemistocytic Differentiation in Isocitrate Dehydrogenase Mutant Astrocytomas: A Histopathological and Survival Analysis
title_sort gemistocytic differentiation in isocitrate dehydrogenase mutant astrocytomas: a histopathological and survival analysis
topic Genetics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182877/
https://www.ncbi.nlm.nih.gov/pubmed/37193447
http://dx.doi.org/10.7759/cureus.37542
work_keys_str_mv AT hassanusman gemistocyticdifferentiationinisocitratedehydrogenasemutantastrocytomasahistopathologicalandsurvivalanalysis
AT amerfaizan gemistocyticdifferentiationinisocitratedehydrogenasemutantastrocytomasahistopathologicalandsurvivalanalysis
AT hussainmudassar gemistocyticdifferentiationinisocitratedehydrogenasemutantastrocytomasahistopathologicalandsurvivalanalysis
AT mushtaqsajid gemistocyticdifferentiationinisocitratedehydrogenasemutantastrocytomasahistopathologicalandsurvivalanalysis
AT loyaasif gemistocyticdifferentiationinisocitratedehydrogenasemutantastrocytomasahistopathologicalandsurvivalanalysis
AT abubakarmuhammad gemistocyticdifferentiationinisocitratedehydrogenasemutantastrocytomasahistopathologicalandsurvivalanalysis